TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7000139
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule followed by A + B (pUVAB)
Study: 25321886
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (Control)
Study: 17392352
Drug: Infliximab dose
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab dose escalation (1.5 mg/kg increments)
Study: 17392352
Drug: Infliximab dose
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab dose escalation(s)
Study: 9875038
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K1 (Konakion MM) - 2 mg at birth, repeated at 7 and 30 days
Study: 9875038
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin K1 - 1 mg
Study: 8040759
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy with an external insulin pump or at least three daily insulin injections, together with frequent daily blood-glucose monitoring
Study: 8040759
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with one or two daily insulin injections and once-daily monitoring
Study: 2723103
Drug: Listerine mouthrinse
Normalized name: Listerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listerine mouthrinse (20 ml, twice daily for 6 months)
Study: 780039
Drug: Metaproterenol sulfate
Normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol sulfate (10 to 20 mg, four times daily for 180 days)
Study: 28615007
Drug: Rhythm-centred music
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm-centred music making (RMM) intervention, 10 weekly sessions
Study: 21859932
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg azithromycin extended-release (ER)
Study: 21859932
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg azithromycin immediate-release (IR)
Study: 10687982
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination and transrectal ultrasonography at PSA 0 to 4.0 ng/ml
Study: 10687982
Drug: PSA 2
Normalized name: Prednisolone Sodium Phosphate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PSA 2 to 4 ng/ml
Study: 10687982
Drug: PSA 0
Normalized name: Prednisolone Sodium Acetate 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA 0 to 4 ng/ml
Study: 9322122
Drug: Serum cytokeratin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum cytokeratin 19 levels > 2 ng/mL in pancreatic duct cell carcinoma
Study: 8195846
Drug: Comparative agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative agents (ampicillin, amoxicillin, cephalosporins, erythromycin, doxycycline, chloramphenicol)
Study: 3026016
Drug: sulbactam/ampicillin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulbactam/ampicillin (50 mg/kg per day, intravenous bolus injection at 6-hr intervals for four to 11 days, mean duration 9 days)
Study: 3026016
Drug: sulbactam/penicillin (1:1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulbactam/penicillin (1:1.2 or 1:1.8 ratio, intravenous bolus injection at 6-hr intervals for four to 11 days, mean duration 9 days)
Study: 29169916
Drug: Lissamine green
Normalized name: LISSAMINE GREEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lissamine green solution (GreenGlo)
Study: 29169916
Drug: Lissamine green
Normalized name: LISSAMINE GREEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lissamine green solution (Lissaver)
Study: 29169916
Drug: OPGreen solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPGreen solution
Study: 22834681
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% (30 ml)
Study: 21163117
Drug: Capecitabine 825
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m² twice daily plus weekly docetaxel 30 mg/m² on days 1 and 8 every 21 days
Study: 15928658
Drug: Capecitabine 500
Normalized name: capecitabine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 500 mg m(‐2) b.i.d.(‐1)
Study: 15928658
Drug: Capecitabine 625
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 625 mg m(‐2) b.i.d.(‐1)
Study: 15497659
Drug: Pegvisomant 10
Normalized name: pegvisomant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant 10 mg/day
Study: 15497659
Drug: Pegvisomant 15
Normalized name: pegvisomant 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant 15 mg/day
Study: 15497659
Drug: Pegvisomant 20
Normalized name: pegvisomant 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant 20 mg/day
Study: 8737522
Drug: Thromboembolism prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboembolism prophylaxis with acenocoumarol during radiation therapy
Study: 8737522
Drug: LMW heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMW heparin during radiation therapy
Study: 8737522
Drug: Acenocoumarol during
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acenocoumarol during radiation therapy
Study: 2065389
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of phentolamine (20‐30 mg/day) and angelicini (150‐450 mg/day)
Study: 2065389
Drug: Conventional supporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional supporting therapy
Study: 14513774
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron preparation
Study: 22818729
Drug: Variety of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variety of vegetables (200 g of each of broccoli, carrots, and snap peas)
Study: 22818729
Drug: Single vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vegetable servings (600 g of broccoli, carrots, or snap peas)
Study: 12149599
Drug: Acarbose (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (2 x 50 mg)
Study: 10215302
Drug: Chronic estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic estrogen replacement therapy
Study: 7793735
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg IV over 30 minutes, followed by 1 mg/kg/hr infusion for 12 hours)
Study: 31280967
Drug: Risankizumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (150 mg subcutaneously at weeks 0 and 4)
Study: 31280967
Drug: Adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (80 mg subcutaneously at randomisation, then 40 mg at weeks 1, 3, 5, and every other week thereafter)
Study: 31280967
Drug: Risankizumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (150 mg)
Study: 20443719
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol gel (1 mg)
Study: 19888035
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol with daily medroxyprogesterone acetate
Study: 17590369
Drug: 1 injection
Normalized name: vitamin K1 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 injection of 1ml Sodium Hyaluronidate (Sinovial)
Study: 17590369
Drug: 2 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 injections of 1ml Sodium Hyaluronidate (Sinovial)
Study: 17590369
Drug: 3 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injections of 1ml Sodium Hyaluronidate (Sinovial)
Study: 3318539
Drug: alpha‐fluoromethyl histidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐fluoromethyl histidine, 100 mg twice daily for 3 weeks
Study: 26831168
Drug: 62.7 ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62.7 ± 3.1 g of IgG IV in 2.6 ± 0.3 L of plasma within 6 h after birth
Study: 26831168
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L of high quality colostrum within 12 h of birth
Study: 25651956
Drug: Intraperitoneal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal ropivacaine (5 mL 1 % Naropin(®))
Study: 30623534
Drug: Saline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (5 mL)
Study: 21910713
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg kg⁻¹ at weeks 0, 2, 6, 14 and 22
Study: 21910713
Drug: Methotrexate 15
Normalized name: methotrexate 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 15 mg weekly (increased to 20 mg weekly at week 6 if PASI response < 25%)
Study: 12548587
Drug: Bisphosphonate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate therapy (clodronate or pamidronate)
Study: 12005179
Drug: Intravenous bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bisphosphonates
Study: 9754791
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (200 mg)
Study: 9754791
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (100 mg)
Study: 9754791
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (50 mg)
Study: 8549083
Drug: Selenium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium treatment in a double-blind placebo-controlled trial on 36 elderly subjects
Study: 8549083
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in a double-blind placebo-controlled trial on 36 elderly subjects
Study: 28368437
Drug: PM01183 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM01183 at 7.0 mg flat dose every 3 weeks (q3wk)
Study: 28368437
Drug: Topotecan (days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (days 1-5 q3wk or weekly q4wk)
Study: 23966309
Drug: Idraparinux (fixed-dose)
Normalized name: Humalog Mix
DrugBank: Idraparinux (DB06406)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idraparinux (fixed-dose)
Study: 23966309
Drug: Conventional anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anticoagulation (dose-adjusted vitamin K antagonists)
Study: 21417594
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pill (OCP) plus myo-inositol (MI) 4 g/die for 12 months
Study: 21417594
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pill (OCP) plus myo-inositol (MI)
Study: 21417594
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pill (OCP) alone
Study: 18802361
Drug: Cluster schedule
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster schedule of specific immunotherapy (6-week duration)
Study: 18802361
Drug: Conventional schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional schedule of specific immunotherapy (14-week duration)
Study: 15250225
Drug: Bronchofiberscopic (BF)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchofiberscopic (BF) injection of 4% lidocaine
Study: 11526793
Drug: Inpatient services
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient services and drugs administration
Study: 28342741
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen cream
Study: 23663021
Drug: Educational preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational preparation for supervision and systematic reflection on supervision.
Study: 19747429
Drug: Azelastine 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 0.15% nasal spray (2 sprays/nostril once daily)
Study: 22287431
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 sprays/nostril once daily)
Study: 19297072
Drug: Pre-operative treatment
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative treatment with triptorelin depot (GnRH-a)
Study: 9669750
Drug: Dalteparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (5000 antifactor Xa units subcutaneously once daily for 35 days)
Study: 9669750
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections for 28 days after 7 days of dalteparin
Study: 3349555
Drug: Edrophonium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.25 mg.kg‐1 and 0.3 mg.kg‐1
Study: 3349555
Drug: Edrophonium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.05 to 0.2 mg.kg‐1
Study: 16792454
Drug: Somatostatin (SMT)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SMT) 250 mg/h
Study: 16792454
Drug: Somatostatin (SMT)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SMT) 500 mg/h
Study: 14557107
Drug: Sensitivity analysis
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitivity analysis for treatment comparisons
Study: 9024009
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (10 micrograms/kg)
Study: 9181154
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (30 micrograms/kg) with PCA
Study: 25636291
Drug: Xinjingjie mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinjingjie mouthrinse (5 mL, 4 times daily during radiotherapy)
Study: 22373953
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (400mg) daily
Study: 22373953
Drug: Ground fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground fish (529±109mg) daily
Study: 15742593
Drug: Preoperative intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intra-articular injection of bupivacaine, morphine, and epinephrine
Study: 15742593
Drug: Postoperative intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative intra-articular injection of bupivacaine, morphine, and epinephrine
Study: 14569937
Drug: R-CHOP chemotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP chemotherapy
Study: 8636761
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg TNF, IFN (0.2 mg), melphalan (10 mg/L limb volume)
Study: 8636761
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg TNF, IFN (0.2 mg), melphalan (10 mg/L limb volume)
Study: 8636761
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg TNF
Study: 8636761
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg TNF
Study: 27604504
Drug: Optimal supportive
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal supportive care (OSC) plus whole brain radiotherapy (WBRT) (20 Gy in five daily fractions)
Study: 15492322
Drug: Fosinopril 20
Normalized name: fosinopril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 20 mg
Study: 3113245
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 micrograms four times daily for seven days)
Study: 31407414
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (IMIQ)
Study: 31407414
Drug: Diclofenac 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 3% gel (DIC)
Study: 23889940
Drug: MgSO(4) 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO(4) 70 mg/kg
Study: 19231315
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 to 40 mg/day)
Study: 12812657
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg and letrozole (2.5 mg) orally q.d. for 8 weeks
Study: 12812657
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg and exemestane (25 mg) orally q.d. for 8 weeks
Study: 11064501
Drug: Triple antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiretroviral therapy
Study: 10997396
Drug: Double antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double antiretroviral therapy
Study: 10997396
Drug: Both double
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both double and triple therapies
Study: 8159300
Drug: Cyclosporin (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (CsA) 5 mg/kg/day in adults, 6 mg/kg/day in children for 9 months, tapered off by 25% every month until complete discontinuation at month 12
Study: 8159300
Drug: Cyclophosphamide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 2.5 mg/kg/day for 8 weeks
Study: 29579042
Drug: Mesalamine treatment
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine treatment (multiple doses over 6 weeks)
Study: 25049132
Drug: Lactobacillus paracasei
Normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus paracasei subsp paracasei L. casei W8 (10^9 CFU)
Study: 25049132
Drug: Lactobacillus paracasei
Normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus paracasei subsp paracasei L. casei W8 (10^10 CFU)
Study: 17610346
Drug: Self-management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management of oral anticoagulant therapy (including a teaching program for self-management followed by 6 months of independent self-management)
Study: 6828828
Drug: Comprehensive rehabilitation
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive rehabilitation programme including diet therapy
Study: 22607165
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control (treatment as usual)
Study: 24060951
Drug: Synbiotics preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics preparation for one month
Study: 19101098
Drug: Methadone dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone dose increase (100mg/day) with split contingency
Study: 19101098
Drug: Methadone dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone dose increase (70mg/day) with split contingency
Study: 19101098
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment during 5-week baseline
Study: 18360012
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg/day)
Study: 17345784
Drug: Control (Rosiglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Rosiglitazone 4 mg/day)
Study: 14659863
Drug: GP IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP IIb/IIIa inhibitors (abciximab) administered intravenously, along with heparin and aspirin during failed thrombolysis or after effective thrombolysis due to pain recurrence and ST segment elevation.
Study: 14659863
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered with full dose of rtpA (100 mg) and standard heparin treatment and aspirin during failed thrombolysis or after effective thrombolysis due to pain recurrence and ST segment elevation.
Study: 14659863
Drug: GP IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP IIb/IIIa inhibitors (abciximab)
Study: 17154747
Drug: Integrative Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative Behavioral Couple Therapy (IBCT)
Study: 6485854
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg glucagon/kg body weight intramuscularly before attempts at reduction
Study: 31671592
Drug: Novel smartphone
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel smartphone application accessed weekly from week 1 to week 6
Study: 26687391
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m², once every 21 days) plus best supportive care
Study: 25180609
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L polyethylene glycol plus ascorbate (PEG+Asc)
Study: 21306085
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri supplementation (containing L. reuteri, ATCC 55730 and ATCC PTA 5289) for 12 weeks
Study: 17437874
Drug: 10% propolis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% propolis solution
Study: 17437874
Drug: 20% propolis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% propolis solution
Study: 17437874
Drug: Hank's Balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hank's Balanced Salt Solution
Study: 11434589
Drug: Oral PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PEG 4000 treatment
Study: 9757919
Drug: pHi-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: pHi-guided therapy
Study: 8141282
Drug: Lower body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower body negative pressure (LBNP) during insulin clamp
Study: 8141282
Drug: Control study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control study (no LBNP) during insulin clamp
Study: 3513564
Drug: Inhaled metaproterenol
Normalized name: metaproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled metaproterenol